Literature DB >> 23339305

Amyloid formation in light chain amyloidosis.

Marina Ramirez-Alvarado1.   

Abstract

Light chain amyloidosis is one of the unique examples within amyloid diseases where the amyloidogenic precursor is a protein that escapes the quality control machinery and is secreted from the cells to be circulated in the bloodstream. The immunoglobulin light chains are produced by an abnormally proliferative monoclonal population of plasma cells that under normal conditions produce immunoglobulin molecules such as IgG, IgM or IgA. Once the light chains are in circulation, the proteins misfold and deposit as amyloid fibrils in numerous tissues and organs, causing organ failure and death. While there is a correlation between the thermodynamic stability of the protein and the kinetics of amyloid formation, we have recently found that this correlation applies within a thermodynamic range, and it is only a helpful correlation when comparing mutants from the same protein. Light chain amyloidosis poses unique challenges because each patient has a unique protein sequence as a result of the selection of a germline gene and the incorporation of somatic mutations. The exact location of the misfolding process is unknown as well as the full characterization of all of the toxic species populated during the amyloid formation process in light chain amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23339305      PMCID: PMC3606678          DOI: 10.2174/1568026611212220007

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  85 in total

1.  Structural relationship of kappa-type light chains with AL amyloidosis: multiple deletions found in a VkappaIV protein.

Authors:  M A Alim; S Yamaki; M S Hossain; K Takeda; M Kozima; T Izumi; I Takashi; T Shinoda
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution.

Authors:  O Epp; E E Lattman; M Schiffer; R Huber; W Palm
Journal:  Biochemistry       Date:  1975-11-04       Impact factor: 3.162

3.  Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.

Authors:  Jonathan S Wall; Vibha Gupta; Matthew Wilkerson; Maria Schell; Remy Loris; Paul Adams; Alan Solomon; Fred Stevens; Chris Dealwis
Journal:  J Mol Recognit       Date:  2004 Jul-Aug       Impact factor: 2.137

4.  The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.

Authors:  Richard W McLaughlin; Janelle K De Stigter; Laura A Sikkink; Elizabeth M Baden; Marina Ramirez-Alvarado
Journal:  Protein Sci       Date:  2006-06-02       Impact factor: 6.725

5.  Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

Review 6.  The Hofmeister series: salt and solvent effects on interfacial phenomena.

Authors:  M G Cacace; E M Landau; J J Ramsden
Journal:  Q Rev Biophys       Date:  1997-08       Impact factor: 5.318

7.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

8.  Tertiary structure of human lambda 6 light chains.

Authors:  P R Pokkuluri; A Solomon; D T Weiss; F J Stevens; M Schiffer
Journal:  Amyloid       Date:  1999-09       Impact factor: 7.141

9.  Systemic and microvascular oxidative stress induced by light chain amyloidosis.

Authors:  Raymond Q Migrino; Parameswaran Hari; David D Gutterman; Megan Bright; Seth Truran; Brittany Schlundt; Shane A Phillips
Journal:  Int J Cardiol       Date:  2009-05-15       Impact factor: 4.164

10.  Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis.

Authors:  Martin Berghoff; Madeera Kathpal; Faisal Khan; Martha Skinner; Rodney Falk; Roy Freeman
Journal:  Ann Neurol       Date:  2003-06       Impact factor: 10.422

View more
  23 in total

Review 1.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

2.  Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Authors:  Gareth J Morgan; Nicholas L Yan; David E Mortenson; Enrico Rennella; Joshua M Blundon; Ryan M Gwin; Chung-Yon Lin; Robyn L Stanfield; Steven J Brown; Hugh Rosen; Timothy P Spicer; Virneliz Fernandez-Vega; Giampaolo Merlini; Lewis E Kay; Ian A Wilson; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

3.  Incomplete Refolding of Antibody Light Chains to Non-Native, Protease-Sensitive Conformations Leads to Aggregation: A Mechanism of Amyloidogenesis in Patients?

Authors:  Gareth J Morgan; Grace A Usher; Jeffery W Kelly
Journal:  Biochemistry       Date:  2017-12-04       Impact factor: 3.162

4.  A kinetic coupling between protein unfolding and aggregation controls time-dependent solubility of the human myeloma antibody light chain.

Authors:  Veronika Džupponová; Veronika Huntošová; Gabriel Žoldák
Journal:  Protein Sci       Date:  2020-10-19       Impact factor: 6.725

5.  Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins.

Authors:  Nicholas L Yan; Diogo Santos-Martins; Enrico Rennella; Brittany B Sanchez; Jason S Chen; Lewis E Kay; Ian A Wilson; Gareth J Morgan; Stefano Forli; Jeffery W Kelly
Journal:  Bioorg Med Chem Lett       Date:  2020-06-16       Impact factor: 2.823

6.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

7.  Solid-state NMR chemical shift assignments for AL-09 VL immunoglobulin light chain fibrils.

Authors:  Dennis W Piehl; Luis M Blancas-Mejía; Marina Ramirez-Alvarado; Chad M Rienstra
Journal:  Biomol NMR Assign       Date:  2016-10-22       Impact factor: 0.746

8.  The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.

Authors:  Gareth J Morgan; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2016-08-26       Impact factor: 5.469

9.  Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.

Authors:  Pamina Kazman; Marie-Theres Vielberg; María Daniela Pulido Cendales; Lioba Hunziger; Benedikt Weber; Ute Hegenbart; Martin Zacharias; Rolf Köhler; Stefan Schönland; Michael Groll; Johannes Buchner
Journal:  Elife       Date:  2020-03-10       Impact factor: 8.140

Review 10.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.